Many patients with hormone receptor-positive (HR+) lymph node-positive (LN+) early stage breast cancer (ESBC) receive adjuvant chemotherapy to reduce the risk of recurrence and improve survival [1]. This evidence concerns the gene NR4A1 and breast carcinoma.